Kornimate/medical-research-clean huggingface dataset:
evaluation of partial versus complete pulpotomy in carious immature molars permanent teeth using bioceramic material

Conditions: Carious Teeth

Summary: one of our major concerns and daily challenges is the management of carious immature permanent teeth, also known as young permanent teeth while preserving the vitality of the dental. preserving radicular pulp tissue in these teeth allows continuing apical maturation and apical closure. diagnosis and treatment of carious immature permanent molars are considered a challenging aspect of daily clinical routine, where constant irritation of the pulp without treatment leads to irreversible pulpitis and necrosis, which impedes the natural root development and its complete formation ; leading at the end to a decision of extracting the tooth .therefore; when treating immature permanent teeth, the main goal is to preserve the vitality of the pulp to guarantee natural root development. pulpotomy is a commonly employed treatment for this procedure involving either the removal of only the outer layer of damaged and hyperemic tissue in exposed pulps (partial pulpotomy or cvek pulpotomy); which is a procedure staged between pulp capping and complete pulpotomy. complete pulpotomy is the total removal of coronal pulp tissue and the placement of a wound dressing on the canal orifice. followed by the placement of a biocompatible material to promote healing and regeneration of the remaining vital pulp tissue. in many studies, mta showed high success rates in treatment of carious immature permanent molars. however, mta is expensive and has poor handling characteristics, a long setting time and no predictable antimicrobial activity. recently, new bioceramics have emerged as promising materials, showing good potential for vital pulp therapy in immature permanent teeth due to their biocompatibility and favorable clinical outcomes. both mta and bioceramics have almost similar compositions, but bioceramics materials contain titanium oxide and calcium phosphate, in addition to the absence of aluminum in its composition. besides, bioceramics can release a high percentage of calcium ions early while maintaining this high percentage for 28 days, in contrast to the mineral trioxide, which showed a lower ability to release calcium ions more slowly. therefore, this study will be conducted to compare the effectiveness bioceramic material in partial and complete pulpotomy of immature permanent molars.

comparing the effectiveness of bioceramic material in partial and complete pulpotomy in carious immature permanent molars.

Eligibility criteria:
inclusion criteria: 1. children with vital immature mandibular first permanent molars; with clinical carious exposure of the pulp and presence of bleeding upon exposure. 2. age ranges from 6-10 years. 3. no history of spontaneous pain. 4. absence of sinus tract, sinus swelling. 5. the posterior teeth could be restored. exclusion criteria: 1-history of spontaneous pain, or pain that wakes up the child at night. 2-teeth with closed apex. 3-teeth with furcation, prominent radiolucency in the periapical region. 4-teeth with excessive mobility. 5-non-restorable molars. -
efficacy and safety of factor viia on rebleeding after surgery for spontaneous intracerebral hemorrhage (ich)

Conditions: Intracerebral Hemorrhage

Summary: although the role of surgical treatment is still controversial, surgical evacuation of intracerebral hematoma is a frequent practice. rebleeding is a frequent complication in patients submitted to hematoma evacuation. it has been reported that smaller postoperative volume of hematoma is associated with a better outcome. the investigators hypothesize that the administration of factor viia (eptacog alfa) immediately after surgical evacuation of the hematoma can reduce postoperative rebleeding. aims of the study: this study will investigate: 1. the efficacy of eptacog alfa in preventing or reducing rebleeding after surgery for spontaneous supratentorial ich; and 2. the safety of product administration

the primary endpoint is the evaluation of efficacy of factor viia (eptacog alfa, novoseven, novo nordisk) on rebleeding after surgery for primary supratentorial ich. all patients included in the study will perform a ct scan within 3 hours before surgery, then immediately after surgery, and 18-30 hours after surgery. the hematoma volume will be evaluated by a multi-slice ct scan. all ct scan images will be sent to the coordinating center where the hematoma volume will be evaluated by a dedicated software by the same investigator who will be unaware of the treatment (investigator- blinded study). safety evaluation: seventeen episodes of thrombotic spontaneous adverse events have been reported after administration of 480,000 standard doses of eptacog alfa in hemophilic patients. these episodes include myocardial infarction, acute cerebrovascular thrombosis, disseminated intravascular coagulation (dic), deep venous thrombosis (dvt) and pulmonary embolism. before and after hematoma removal will be evaluated ecg, myocardiac enzymes, coagulation profile, ct scan (looking for ischemic events) and venous echodoppler ultrasound of lower extremities.

Eligibility criteria:
inclusion criteria: * male or female, aged 18-75 years inclusive * intraparenchymal primary supratentorial intracerebral hemorrhage requiring surgical evacuation * any glasgow coma score (gcs) score * surgery expected to be performed within 24 hours from symptoms onset exclusion criteria: * age below 18 * intraparenchymal hematoma secondary to rupture of cerebral aneurysm or bleeding of arteriovenous (a-v) malformation or cerebral tumors * contemporary involvement in another study * pregnancy * myocardial infarction in the six months preceding enrolment * coronary or carotid stents positioned in the six months preceding enrolment * solid organ transplant patients (e.g., heart, lung, liver, kidney) * pregnancy * myocardial infarction in the six months preceding enrolment * coronary and carotid stents positioned in the six months preceding enrolment * solid organ transplant patients (e.g., heart, lung, liver, kidney)

Keywords: spontaneous intracerebral hemorrhage ich intracerebral rebleeding cerebral hematoma evacuation cerebral hematoma volume
human algorithm interactions for acute respiratory failure diagnosis

Conditions: Acute Respiratory Failure

Summary: artificial intelligence (ai) shows promising in identifying abnormalities in clinical images. however, systematically biased ai models, where a model makes inaccurate predictions for entire subpopulations, can lead to errors and potential harms. when shown incorrect predictions from an ai model, clinician diagnostic accuracy can be harmed. this study aims to study the effectiveness of providing clinicians with image-based ai model explanations when provided ai model predictions to help clinicians better understand the logic of an ai model's prediction. it will evaluate whether providing clinicians with ai model explanations can improve diagnostic accuracy and help clinicians catch when models are making incorrect decisions. as a test case, the study will focus on the diagnosis of acute respiratory failure because determining the underlying causes of acute respiratory failure is critically important for guiding treatment decisions but can be clinically challenging. to determine if providing ai explanations can improve clinician diagnostic accuracy and alleviate the potential impact of showing clinicians a systematically biased ai model, a randomized clinical vignette survey study will be conducted. during the survey, study participants will be shown clinical vignettes of patients hospitalized with acute respiratory failure, including the patient's presenting symptoms, physical exam, laboratory results, and chest x-ray. study participants will then be asked to assess the likelihood that heart failure, pneumonia and/or chronic obstructive pulmonary disease (copd) is the underlying diagnosis. during specific vignettes in the survey, participants will also be shown standard or systematically biased ai models that provide an estimate the likelihood that heart failure, pneumonia and/or copd is the underlying diagnosis. clinicians will be randomized see ai predictions alone or ai predictions with explanations when shown ai models. this survey design will allow for testing the hypothesis that systematically biased models would harm clinician diagnostic accuracy, but commonly used image-based explanations would help clinicians partially recover their performance.


Eligibility criteria:
inclusion criteria: * physicians, nurse practitioners, and physician assistants that care for patients with acute respiratory failure as part of their clinical practice exclusion criteria: * physicians, nurse practitioners, and physician assistants that only provide patient care in outpatient settings

Keywords: artificial intelligence diagnostic accuracy computer assisted diagnosis biased model
subclinical hypothyroidism and mind in the elderly

Conditions: Subclinical Hypothyroidism

Summary: some recommendations of expert consensus on subclinical hypothyroidism (sh) are controversial in those areas with not enough information to reach a conclusion, such as not recommending treatment with thyrotrophic hormone of 4-10 mui/l and free thyroxin in normal range. the body changes or symptoms at this stage are often mistaken as aging. there are studies showing significant changes in heart (slow rate, lower ejection fraction, diastolic dysfunction); hypercholesterolemia, dysfunction cognitive abilities (memory attention...). the prevalence of sh increases with age, reaching 14% over 65 years old. this age group increase as the population ages highlights the need for evidence to improve recommendations for the elderly. neuropsi is a validated neuropsychological test sensible for mild cognitive alterations. it can be applied to individuals with little schooling. this study aims to determine positive change in cognitive abilities (neuropsi), ejection fraction, and body percent of lean and adipose tissue without adverse effects, placebo versus thyroxin supplement to keep thyroid-stimulating hormone (tsh) between 0.5-2.5 mui/l in elderly with tsh 4-10 miu/l.

screening, subjects \> 59 y/o with out exclusion criteria to identify hs, started in october 15, 2008. due to difficulties getting the placebo for the assay, by january halted the screening. at the end of may we got the donation from merck pharmaceuticals. the protocol original dates changed as follows: * restart screening june 20 to end in august 2009; * enrolling start at the end of june (the already identified); * end enrolling october 2009; * follow up will end in may 2010. note: 150 of the screened subjects will be from randomly selected homes at fomerrey 19 to allow prevalence estimation. * enroling ended until june 2010 * follow up stil ungoing final measures will be done at the end of 2011

Eligibility criteria:
inclusion criteria: * tsh between 4 and 10 mui/l inclusive exclusion criteria: * known and treatment of thyroideal disease * arrythmia * anticoagulant treatment * dementia * disease leading to dementia (acv, liver....)

Keywords: subclinical hypothyroidism elderly mild cognitive impairment neuropsychological test neuropsi
clinical and biological study of sub-pigmentation during infantile cystinosis

Conditions: Cystinosis

Summary: the purpose of this study is to determine the molecular mechanism of this disease and to research the relationship between cystinosis and skin phenotype.


Eligibility criteria:
inclusion criteria: 1. cystinosis 2. known ctns mutation exclusion criteria: 1. patient with corticotherapy treatment 2. patient with immunosuppressant treatment
intrarectal misoprostol in postpartum haemorrhage

Conditions: Postpartum Haemorrhage

Summary: postpartum haemorrhage (pph) remains the major cause of maternal mortality in france. the most efficient treatment of severe pph is sulprostone which is associated with cardiac complications. the objective of this study was to assess the efficacy and the safety of intrarectal misoprostol for curative postpartum haemorrhage treatment. we conducted a multicenter double blind randomized placebo control trial between june 2004 and december 2007, among consenting women with postpartum haemorrhage and failure to oxytocin treatment. our main criteria of judgement was quantification of blood loss and the use of sulprostone between the two groups using either misoprostol intrarectal tablets (5x200mg ) or placebo in similar opaque introducer.


Eligibility criteria:
inclusion criteria: * older than 18 yrs old * giving birth after 32 weeks of amenorrhea * post-partum haemorrhage due to atony * inefficiency off the first line treatment * written signed consent form exclusion criteria: * known allergy to prostaglandin * haemostasis anomalies before labour * anticoagulant treatment * fetal death * accreta or percreta placenta * under 18 years * delivery before 32 weeks of amenorrhea * post-partum bleeding not suspected to be due to atonic uterus
behavioral weight loss treatment for individuals with food addiction

Conditions: Food Addiction; Overweight and Obesity; Weight Loss

Summary: the purpose of this research study is to examine how well an existing weight loss treatment works for individuals with food addiction. treatment will consist of a preliminary 12-week rct pilot of the feasibility and effectiveness of behavioral weight loss (bwl) compared to a waitlist control.


Eligibility criteria:
inclusion criteria: * bmi 25-50 kg/m2 * meets criteria for food addiction (based on the self-report score from the yale food addiction scale) * available for the duration of the treatment (3 months) * read, comprehend, and write english at a sufficient level to complete study-related materials. * availability of internet to participate in study interventions (i.e., electronic smart scales) exclusion criteria: * co-existing psychiatric condition that requires hospitalization or more intensive treatment (e.g., bipolar mood disorders, psychotic illnesses, severe depression). * reports active suicidal or homicidal ideation * current anorexia or bulimia nervosa * endorsing current or history of heart trouble/chest pain. * breast-feeding or pregnant, or planning to become pregnant during the study. * history of stroke or myocardial infarction. * current or recent (within 12 months) drug or alcohol dependence * currently receiving effective treatment for eating or weight loss, including individual who received bariatric surgery within the past five years * currently participating in another clinical study.
mindfulness intervention for overweight primary care patients

Conditions: Overweight; Obesity

Summary: mindfulness has been applied in the united states and europe to improve both physical and psychological health, however, it is still poorly studied in brazil. mindfulness, or its lack, may also have particular relevance to obesity and eating disorders, reducing the episodes of "binge eating", which are partly responsible for weight regain for many people, and improving the eating behavior in order to promote awareness of emotional states which distort the physiological signals generated by the process. the hypothesis is that mindfulness-based interventions (mbi) as well as specific programmes focused on conscious eating, as mindfulness based eating awareness training (mb-eat) can, in short time, and in a sustainable fashion, improve biochemical, psychometric and anthropometric parameters in primary care patients with overweight.

a randomized-controlled trial will be conducted to compare treatment-as-usual (tau) in primary care combined a generic mbi (with 8 sessions) developed by our research group, called "mindfulness-based health promotion" (mbhp) program versus tau plus mb-eat. it will be included women aged ≥18 and \< 60, literate , with a bmi (body mass index) ≥ 25 kg/m2. the primary outcome is the improvement of the eating behaviour measured by debq. secondary outcomes are: it is expected improvement of nutritional status (reduction of body weight by at least 5% of the weight) along the intervention, as well as maintenance of this (without weight regain) which could lead to the prevention of multiple morbidities related to excess body weight. will be assessed the levels of mindfulness, stress, anxiety (psychometric scale and serum cortisol) and self-compassion. there will be performed basal (baseline), at post-intervention, 3 and 6 months follow-up measurements. the control group will receive the intervention that has been shown to be more effective at the end of the study (mbhp or mb-eat).

Eligibility criteria:
inclusion criteria: * women aged 18-59 years old, literate; * primary care patients who have the body mass index (bmi) ≥25kgm2 and \< 40kg/m2 * people who have an interest in the objectives of this study and consented to be randomized to one of three arms. * those who have participated in 75% of sessions or only two absences in the program exclusion criteria: * those who are under pharmacological treatment for overweight; * pregnant women; * those who have problems with substance use (drugs and alcohol); * untreated hypothyroidism or hyperthyroidism; * those who are in acute phase of depression (less than 6 months in depression); schizophrenia or psychotic disorders or who are using drugs that cause cognitive attentional and concentration losses (such as powerful anti-anxiety drugs); * current practitioners of mindfulness, meditation, yoga, or the like, in the last 6 months (with formal practice at least once a week); * those who have undergone any type of bariatric surgery.

Keywords: mindful eating overweight primary care randomized clinical trial
computerized anxiety sensitivity treatment for opioid use disorders

Conditions: Opioid Use Disorder

Summary: the primary aim of the current project is to test the acceptability and feasibility of a computerized intervention, titled computerized anxiety sensitivity treatment (cast), delivered to veterans seeking treatment for an opioid use disorder. the second aim of the study is to examine the utility of cast by gathering data on symptom change. the final aim of the current study is to test the effects of cast on rates of attendance and retention in a substance use disorder treatment (sudt) program.

the pilot project will examine the effects of a brief, one-session computerized intervention delivered to veterans seeking treatment for an opioid use disorder. the opioid epidemic in the united states (us) is having a disproportionate impact on veterans. indeed, veterans are twice as likely to die from an accidental opioid overdose than members of the general population, even after accounting for gender and age distribution. although many individuals with an opioid addiction seek treatment, a large proportion drop out prematurely and/or relapse, highlighting the need to identify modifiable factors that may contribute to this process. one variable that may be useful in understanding attrition in addiction treatment is anxiety sensitivity (as). as is a well-established psychological risk factor reflecting the tendency to fear anxious arousal due to the belief that this arousal will have harmful physical, mental, and/or social consequences. as is elevated in opioid use populations and predicts treatment dropout among opioid users. importantly, research suggests that as is highly malleable. despite this, to our knowledge no published research to date has systematically explored the utility of as reduction protocols among opioid users. the first aim of the current project is to test the acceptability and feasibility of a brief, one-session computerized as treatment (cast) delivered to veterans seeking treatment for an opioid use disorder. because this is a pilot project and the study will likely be underpowered to detect treatment effects, we will not emphasize symptom reduction. nevertheless, a second aim of the current project is to examine the utility of cast by gathering data on symptom change. finally, a third aim of the current project is to examine the effects of cast on rates of attendance and retention in a substance use disorder treatment (sudt) program.

Eligibility criteria:
inclusion criteria: * veterans must be diagnosed with an opioid use disorder exclusion criteria: * less than 18 years of age * actively suicidal * actively psychotic * uncontrolled bipolar disorder (i.e., not stable on medications for at least one month)

Keywords: veterans anxiety sensitivity opioid use disorder intervention
post-market clinical follow-up study with aspirex®s to assess the safety and effectiveness in the treatment of dvt

Conditions: Deep Vein Thrombosis; Bypass Complication; Dialysis Shunt; Stent Occlusion

Summary: the aspirex®s endovascular system is a rotating and aspirating catheter system. it is intended to be used for the percutaneous transluminal removal of fresh thrombotic or thromboembolic material from native blood vessels (or vessels fitted with stents, stent grafts or native or artificial bypasses) outside the cardiopulmonary, coronary and cerebral circulations. capturex® , a catheter with a filter basket, is intended to be used for the filtering of emboli from blood vessels during potentially embolizing procedures on the patient. aspirex®s and capturex® are ce-marked (class iii) medical devices. in this study the effectiveness and safety in the removal of thrombi in veins is assessed under real life setting.


Eligibility criteria:
inclusion criteria: 1. acute thrombotic or thromboembolic occlusion (onset of pain \< 14 days) 2. age \> 18 years 3. written informed consent form exclusion criteria: 1. patient not suitable for thrombectomy 2. fracture area of broken stents 3. known or suspected allergy to any of the components of the system or to a medicinal product to be administered in connection with the planned procedure 4. persistent vasospasm 5. severe coagulatory disorders 6. patients with thrombophilia 7. aneurysmatically altered vessel segments on target zone or on passage of catheter 8. known or suspected infection, especially of the puncture site or the vessel segment being treated 9. known, unhealed pre-existing mechanical damage to the vessel wall, especially caused by surgical procedures or interventional complications 10. immature or not fully healed dialysis accesses or bypass grafts 11. female subjects of childbearing capacity who are not willing to employ contraceptive measures 12. pregnant or breast feeding subjects 13. subjects who, in the opinion of the investigator, will be inappropriate for inclusion into this study or will not comply with requirements of the study 14. subjects who are lawfully kept in an institution 15. subjects who do not have the mental or physical ability to comply with time schedules and further study procedures 16. current participation in any other clinical study (medicinal, medical device) or within the last 30 days prior to screening

Keywords: mechanical thrombectomy